NCT03753204CompletedPhase 1/2
Salt-Sensitivity and Immunity Cell Activation
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events. The precise mechanisms of how dietary salt contributes to blood pressure elevation, renal injury, and cardiovascular disease remains unclear. Our data indicated that monocytes exhibit salt sensitivity, and the investigators hypothesize that of salt sensitivity of these and similar immune cells correlate with the hypertensive response to salt intake. Currently, the research tools for diagnosing salt-sensitivity are costly, time consuming and laborious. In this study the investigators will identify monocyte salt-sensitivity as a marker of salt-sensitive hypertension.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 20 Nov 2018
- Start date
- 1 Sept 2021
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- High blood pressure
- NCT number
- NCT03753204
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 36
- From 1 Sept 2021 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute cardiovascular event(s) within the previous 6 months
- Current excessive alcohol or illicit drug use.
- Blood pressure below the inclusion criteria levels after discontinuation of therapy
- Presence of metal implants such as artificial joints.
- Concomitant diabetes mellitus, type I or II.
Other illness
- Autoimmune disease.
Other
- Claustrophobia precluding obtaining an MRI
- Inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol.
- Recent vaccination
- Younger or older that inclusion criteria.
- Pregnancy.
Who the study is looking for
- We will perform a pilot analysis in 20 hypertensive subjects controlled for gender (50% men, 50% women), age (18-60 years),
- New or pre-existing diagnosis of essential hypertension defined as systolic blood pressure \>140 mmHg or \>90 mmHg diastolic or taking antihypertensive medications regardless of current blood pressure.
- BMI (18.5-24.9).
- Only subjects who give informed consent will be studied.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.